Major Takeda Boost To Japan’s iPSC Ambitions
This article was originally published in PharmAsia News
Executive Summary
If further industry validation were needed of the attractions of Japan's flagship induced pluripotent stem cell (iPSC) technology, it has now been provided in a major practical research collaboration involving the country's largest pharma firm.
You may also be interested in...
Interview: Setting The Course For Takeda’s R&D Future
Dr. Andrew Plump joined Takeda from Sanofi in 2015 as the Japanese company's chief medical and scientific officer. In his current position, based in the US, he leads the global R&D organization, which has seen much fundamental change over the past 18 months.
Quick Listen: Scrip's Five Must-Know Things
In this week's podcast edition of Five Must-Know Things: the shifting sands of pharma R&D; big pharma oncology strategies; semaglutide’s promise in heart failure; AstraZeneca looks to multiple cancer modalities; and an interview with Astellas’s chief strategy officer.
Quick Listen: Scrip's Five Must-Know Things
In this week's podcast edition of Five Must-Know Things: Genmab buys into ADCs; Roivant set to take on AbbVie in uveitis; Ipsen signs firs ADC pact; South Korea looks to build biotech momentum; and the end of the road for Acorda.